Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 15, Issue 6, Pages 350-351Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41571-018-0025-z
Keywords
-
Categories
Funding
- Aptevo
- Aragon
- Astellas
- AstraZeneca
- Bayer
- Hoffman LaRoche
- Janssen
- Medivation
- Pfizer
Ask authors/readers for more resources
After almost 20 years of negative trials of novel therapies for patients with nonmetastatic castration-resistant prostate cance (nmCRPC), two androgen receptor antagonists have shown favourable outcomes in phase III trials involving patients with high-risk nmCRPC. Herein, the history of nmCRPC and clinical trials in this disease setting are discussed and a perspective on molecular imaging and clinical management of nmCRPC is offered.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available